Forest Laboratories to Exceed Fiscal 2005 Second and Third Quarter Mean Earnings Per Share Estimates
October 04 2004 - 5:30PM
PR Newswire (US)
Forest Laboratories to Exceed Fiscal 2005 Second and Third Quarter
Mean Earnings Per Share Estimates NEW YORK, Oct. 4
/PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an
international pharmaceutical manufacturer and marketer, today
announced that it expects its performance for the fiscal 2005
second quarter ended September 30, 2004 to exceed current consensus
estimates. The Company projects that diluted earnings per share
will exceed the current First Call mean estimate of $0.63 per share
by approximately 20%. In the second quarter of last fiscal year
Forest earned $0.49 per share. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) The
Company indicated that the principal reason for the better than
anticipated performance in the quarter is strong net sales volume
of approximately $850 million. Sales of its antidepressant
franchise were approximately $670 million with Lexapro(R) sales of
approximately $415 million and Celexa(R) sales of approximately
$255 million. Namenda(R) sales amounted to approximately $80
million. Inventory levels for the Company's products remained
stable at the wholesaler and distributor level. Other income for
the quarter included the first co-promotion payment from Sankyo of
approximately $12 million on the shared profits of Benicar(R). This
payment is based upon a partial quarter of profitability following
recovery by Sankyo of cumulative expenses related to the
development, launch and marketing of the product. Research and
development expense in the quarter was approximately $65 million
and includes a payment to Glenmark Pharmaceuticals pursuant to the
collaboration agreement announced during the quarter. The Company
also indicated that, in the absence of a generic version of Celexa
during its fiscal third quarter ending December 31, 2004, earnings
per share for that quarter will also exceed the current mean
estimate of $.65 per share and be comparable to earnings per share
in the fiscal second quarter. Forest plans to issue its second
quarter fiscal 2005 earnings on Monday, October 18, 2004 and will
hold an investor conference call to discuss the results. About
Forest Laboratories and Its Products Forest Laboratories' growing
line of products includes: Namenda(R) (memantine HCl), an
N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer's disease; Lexapro(R)
(escitalopram oxalate), an SSRI antidepressant indicated for the
initial and maintenance treatment of major depressive disorder and
for generalized anxiety disorder; Celexa(R) (citalopram HBr), an
antidepressant; Benicar(R) * (olmesartan medoxomil), an angiotensin
receptor blocker indicated for the treatment of hypertension;
Benicar HCT(TM) (olmesartan medoxomil hydrochlorothiazide), an
angiotensin receptor blocker and diuretic combination product
indicated for the second-line treatment of hypertension; Campral(R)
(acamprosate calcium), a glutamate receptor modulator, indicated
for the maintenance of abstinence from alcohol in patients with
alcohol dependence who are abstinent at treatment initiation when
used in combination with psychosocial support; Aerobid(R)
(flunisolide), an inhaled steroid indicated for the treatment of
asthma; and Tiazac(R) (diltiazem HCl), a once-daily diltiazem,
indicated for the treatment of angina and hypertension. *
Benicar(R) is a registered trademark of Sankyo Pharma, Inc. Except
for historical information contained herein, this release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are
subject to risks and uncertainties that affect our business,
including risk factors listed from time to time in the Company's
SEC reports, including the Company's Annual Report on Form 10-K for
the fiscal year ended March 31, 2004, and Quarterly Reports on Form
10-Q for the period ending June 30, 2004. Actual results may differ
materially from those projected.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President - Investor Relations of Forest Laboratories, Inc.,
+1-212-224-6714, or Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024